• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

  • Vestibo 24mg 60 tablets — Made in Bulgaria — Free Delivery


    Brand: Balkanpharma-Dupnitsa AD
    Product Code: Vestibo 24mg
    Availability: 5-10 Days
    $46.13
    Add to Cart

    Product description 

    Vestibo is indicated for the treatment of Meniere's disease and syndrome characterized by three main symptoms:
    • dizziness, sometimes accompanied by nausea and vomiting;
    • hearing loss (hard of hearing)
    • tinnitus.
    Vestibo is also prescribed for the symptomatic treatment of vestibular vertigo of various origins.

    Compound

    Active ingredient: betahistine;
    1 tablet contains betahistine dihydrochloride 24 mg;
    Excipients: povidone, microcrystalline cellulose, lactose, colloidal silicon dioxide, crospovidone, stearic acid.

    Contraindications

    Hypersensitivity to or to any of the excipients of the preparation.
    Pheochromocytoma.

    Application features

    Use during pregnancy or lactation
    Pregnancy. There are insufficient data on the use of betahistine in pregnant women.
    The results of animal studies are insufficient to assess the effect on pregnancy, embryo/fetal development, childbirth and postnatal development. The potential risk to humans is unknown. Betahistine should not be used during pregnancy unless clearly necessary.
    breastfeeding period. It is not known whether betahistine passes into breast milk. Animal studies on the penetration of betahistine into milk have not been conducted. The benefit to the mother should be weighed against the benefits of breastfeeding and the potential risk to the baby.
    Children
    Due to the lack of data on the safety and efficacy of betahistine, the preparation is not recommended for children (under the age of 18 years).
    The ability to influence the reaction rate when driving vehicles or operating other mechanisms
    Betahistine is indicated for the treatment of Meniere's syndrome, which is characterized by a triad of main symptoms: dizziness, hearing loss, tinnitus, as well as for the symptomatic treatment of vestibular vertigo. Both conditions can negatively affect the ability to drive and use machines. According to clinical studies that studied the effect on the ability to drive a car and work with other mechanisms, betahistine did not affect or had an insignificant effect on this ability.

    Dosage and administration

    The daily dose for adults is 24-48 mg, evenly distributed for admission during the day.
    The dose should be selected individually, depending on the effect. Reduction of symptoms is sometimes observed only after two to three weeks of treatment. The best results are sometimes achieved when taking the preparation for several months. There is evidence that treatment early in the disease prevents disease progression and/or hearing loss in later stages.

    Overdose

    There are several cases of preparation overdose. Some patients experienced mild to moderate symptoms (nausea, drowsiness, abdominal pain) after taking the preparation at a dose of up to 640 mg. More serious complications (convulsions, cardiopulmonary complications) have been observed with the deliberate intake of high doses of betahistine, especially in combination with an overdose of other preparations.
    Treatment
    Treatment of overdose should include standard supportive measures.

    Adverse reactions

    The following adverse reactions were observed in patients with such a frequency: very often (≥ 1/10), often (≥1/100 to <1/10), infrequent (from ≥1/1000 to <1/100), rare (from ≥ 1/10000 to <1/1000), rare (<1/10000).
    From the gastrointestinal tract
    Often: nausea and dyspepsia.
    From the side of the nervous system
    Often: headache.
    Adverse reactions, the frequency of which is unknown.
    From the side of the immune system
    Hypersensitivity reactions such as anaphylaxis.
    From the gastrointestinal tract
    Complaints of minor stomach upsets (vomiting, gastrointestinal pain, bloating and flatulence). These side effects usually disappear when the preparation is taken with food or when the dose is reduced.
    From the skin and subcutaneous tissue
    Hypersensitivity reactions of the skin and subcutaneous fat have been observed, in particular angioedema, rash, itching and urticaria.
    Interaction with other medicinal products and other forms of interaction
    In vivo studies aimed at studying interactions with other preparations have not been conducted. Based on in vitro study data, suppression of cytochrome P450 enzyme activity in vivo is not expected.
    In vitro data suggest that betahistine metabolism is inhibited by preparations that inhibit monoamine oxidase (MAO) activity, including MAO subtype B (eg, selegiline). It is recommended to be careful with the simultaneous use of betahistine and MAO inhibitors (including selectively subtype B MAO).
    Since betahistine is a histamine analog, the interaction of betahistine with antihistamines could theoretically affect the effectiveness of one of these preparations.

    Storage conditions

    Store in original packaging at temperatures not exceeding 25°C.
    Keep out of the reach of children.
    Shelf life - 3 years.

    There are no reviews for this product.